Mammoth Biosciences
Matthew Verosloff is a highly skilled scientist with extensive experience in synthetic biology and gene editing. Currently serving as a Senior Scientist I at Mammoth Biosciences since September 2024, Matthew focuses on developing genetic medicines through innovative CRISPR applications. Previously, as a Scientist II at ReCode Therapeutics, Matthew led projects integrating gene editing with cutting-edge lipid nanoparticle technology. Earlier roles at Mammoth Biosciences involved harnessing Cas enzymes for novel assay development and employing high-throughput processes. A PhD holder in Synthetic Biology from Northwestern University, Matthew's academic background includes significant research on RNA mechanisms and CRISPR systems, complemented by a Master's in Biotechnology from the University of Pennsylvania and a Bachelor's in Biology from Rutgers University.
This person is not in any teams
Mammoth Biosciences
3 followers
Mammoth Biosciences is harnessing the diversity of nature to power the next-generation of CRISPR products. Through the discovery and development of novel CRISPR systems, the company is enabling the full potential of its platform to improve lives by reading and writing the code of life. Mammoth aims to democratize disease detection with an easy and affordable point-of-care test that allows real-time and simultaneous detection of multiple conditions. By leveraging its internal research and development and exclusive licensing to Cas12, Cas13, Cas14, and CasΦ, Mammoth can provide enhanced diagnostics and genome editing for life science research, healthcare, agriculture, biodefense and more. Based in San Francisco, Mammoth Biosciences is co-founded by CRISPR pioneer Jennifer Doudna and principal founders Trevor Martin, Janice Chen, and Lucas Harrington. The firm is backed by top institutional investors including Mayfield, NFX, and 8VC, Decheng and leading individual investors including Brook Byers, Tim Cook, and Jeff Huber.